Back

Cardioprotective efficacy of combined therapy with azilsartan, indapamide, and nitrendipine in patients with essential hypertension

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Hypertension target organ damage Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Assistant Professor Zaringiz Mashkurova

Republican Specialized Scientific Practical Medical Center Of Cardiology, Tashkent (Uzbekistan)

8 More presentations in this session

Presentation thumbnail
Orthostatic blood pressure changes and incident atrial fibrillation in patients with hypertension: Insights from the SPRINT trial
Doctor J. Wang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Diagnostic and prognostic value of ECG-predicted hypertension mediated left ventricular hypertrophy using machine learning
Doctor H. Naderi (London, GB)
Abstract Slides Video
Presentation thumbnail
Carotid-Femoral pulse wave velocity progression in hypertensive patients is associated with subsequent cardiovascular outcomes
Doctor A. Maloberti (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Cardiac magnetic resonance (CMR) height-based allometric scaling in Southeast Asians; implications in the diagnosis and prognosis of left ventricular hypertrophy (LVH): the REMODEL study
Mr C. Lee (Dundee, GB)
Abstract Slides Video
Presentation thumbnail
Relationship between renin, aldosterone, aldosterone-to-renin ratio and left ventricular mass index in young adults
Doctor R. Ananda (Melbourne, AU)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertension target organ damage

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Real-world analysis exploring the association between anti-hypertensive therapy with perindopril-based single-pill combinations (SPC) and cardiovascular outcomes and all-cause mortality in Italy
thumbnail
Congress Presentation
The impact of cardiovascular risk factors on longitudinal changes in cardiac structure and function in an older population of hypertensive patients
thumbnail
Congress Presentation
Effects of sacubitril-valsartan alone or in combination with dapagliflozin on aging-related heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources